Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:30 AM ET, Wednesday, January 30, 2013
Posted on January 29, 2013 at 21:19 PM EST
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of KYNAMRO™ (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). CONFERENCE CALL At 09:30